5 thousand subscribers
4 thousand videos
Lili Brillstein Discusses Incorporating Social Determinants of Health Into Value-Based Care
Importance of Relapse Prevention in Schizophrenia
Akebia Therapeutics' CEO on Mechanisms of HIF-PHI Candidate
Complexity of Chronic Thromboembolic Pulmonary Hypertension
Dr John McMurray Explains the Heart Failure Benefits of Dapagliflozin in Diabetics and Non-Diabetics
Mavis Asiedu-Frimpong Explains How Medicaid Aims to Provide a Broad Spectrum of Personalized Care
Dr Peter McAllister Discusses Lessons Learned From COVID-19 for Migraine Treatment
Dr Deepak Bhatt Highlights Latest REDUCE-IT Data
Dr Timothy Yap: Rucaparib/Sacituzumab Govitecan Combo Effective Against Triple-Negative Disease
Dr Mark Fendrick Explains Bipartisan Appeal of Value-Based Insurance Design
Dr Ruth Ann Marrie Discusses Comorbidities in Multiple Sclerosis
Dr Stephen Silberstein Compares the Effects of Erenumab on Chronic, Episodic Migraine
Dr Peter McAllister Shares How COVID-19 Altered Patients' Migraine Symptoms
Whole-Person Health Care: Integrating Mental and Behavioral Health Into Primary Care
Dr Neal Jain on the Real-World Results of Dupilumab in Asthma
Dr Joshua Rein Offers Insights on Cannabis Use for Chronic Kidney Disease
Dr George Bakris Compares FIDELIO-DKD Renal Outcomes With Those of SGLT-2 Inhibitor Trials
Marc Boutin Examines the Underutilization of Patients
Value of Quality-of-Life Metrics
Dr Maura Abbott Explains How Vaccine Form Determines Patient Contraindications
Economic Burden of Atopic Dermatitis Treatment
Dr Stephen Silberstein on How Patients Are Reacting to CGRP Inhibitors
Understanding the Transition From RRMS to SPMS
Dr Jan Hillert on the Misclassification of SPMS as RRMS
Dr Jane F. Barlow Discusses Potential New Reimbursement Models for New, High-Cost Therapies
Dr Jonathan Avery on Causes, Consequences of Concurrent Mental Illness and Substance Use
Quality Metrics and Patient-Reported Outcomes
What is Interstitial Lung Disease?
Interstitial Lung Disease: Guidelines for Therapy
First-line Therapy for HR-positive, HER2-negative, mBC
The Nonpharmacological Treatment of Diabetes
Cardiovascular Risk Management
Economic Burden of Cardiovascular Disease
Dyslipidemia: Strategies Used to Reduce CV Risk
MDS Management: Challenges With Chemotherapy
Risk Assessment for Cardiovascular Disease
Role of Anemia in CKD
Dr. Matthew Budoff on the Benefits of Cardiac CT Use
Overview of Chronic Kidney Disease (CKD)
Dr Daniel Laroche Discusses Eye-Related Implications, Barriers to Eye Care Amid COVID-19
HIF Stabilizers: Management of Anemia in CKD
Future Treatment of Anemia in CKD: Impact of HIF Stabilizers
Steps to Reduce Racial Cancer Disparities Include Supporting Minority Doctors, Diversifying Trials
HIF Stabilizers for Anemia in CKD: Phase 3 Trials
Examining the Impact of Behavioral Health Costs on Overall Health Care Spending
Dr Milton Packer Discusses the Combined Impact of EMPEROR-Reduced, DAPA-HF
Dr Javed Butler on SGLT-2 Inhibitors' Role in Preventing HF
Dr Paulus Kirchhof Discusses EAST AFNET 4 Trial Results
Dr Stewart Factor on Implications, Treatment of OFF Periods in Parkinson Disease
Using Reimbursement Models to Overcome Oncology Care Gaps
